Orchid Pharma gets nod from USFDA for Risedronate Sodium Tablets

14 May 2019 Evaluate

Orchid Pharma has received ANDA approval from United States Food and Drug Administration (USFDA) for Risedronate Sodium Tablets USP, 30 mg and 35 mg. Risedronate sodium tablets are a bisphosphonate indicated for the treatment and prevention of Osteoporosis.

Orchid Pharma is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients and finished dosage forms. It is also engaged in research of new drugs.

Orchid Pharma Share Price

723.40 -16.85 (-2.28%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×